NICE decision on olaparib for ovarian cancer angers charities

  The Institute of Cancer Research has voiced its disappointment at the recent NICE decision on olaparib for women with BRCA mutated ovarian cancer infurther draft guidance. The drug olaparib helps women with ovarian cancer who have a faulty BRCA gene, with studies showing it extends lives by an average of 11 months. The treatment is the first cancer drug approved in this country that responds to inherited genetic mutations, but in June NICE said the £48,000 per year price tag of the drug, which could benefit 450 women a year, could not be justified. ProfessorPaul Workman, Chief Executive of The Institute of